Playback speed
10 seconds
ESMO 2023 Insights: "EV-302/KEYNOTE-A39 Study of Enfortumab Vedotin + Pembro vs. Chemo in Previously Untreated la/mUC"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Thomas Powles
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Thomas Powles
272 views
October 30, 2023
Login to view comments.
Click here to Login